Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111696 · ClinicalTrials.gov registry record · Phase 1
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
A Phase 1 study of Malignant Melanoma, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00111696 is a Phase 1 study of Malignant Melanoma that has completed, run by MedImmune. The registered enrollment target is 18 participants, below the 183-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00111696, a Phase 1 study of Malignant Melanoma, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.
Conditions Studied
Interventions
- BIOLOGICAL MEDI-522
Study Locations (1)
Pennsylvania
- University Of Pittsburgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111696
The ClinicalTrials.gov registry entry for NCT00111696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (90% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 1 intervention - of which MEDI-522 is the first listed.
NCT00111696 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00111696 about?
NCT00111696 is a clinical study titled "Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma". To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.
What is the current status of trial NCT00111696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2005-05. Estimated completion is 2007-11.
What conditions does trial NCT00111696 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT00111696?
The interventions under investigation include: MEDI-522 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00111696?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00111696 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.